Clinical trials: SCCHN
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer
The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous…
- Trial name
- NCT02499120
- Testing
- palbociclib, Cetuximab
- Where
- 71 sites in United States, Czechia and 13 more
- Volunteers
- 125 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor
- Trial name
- NCT05099549
- Testing
- AFM24, SNK01
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- NKGen Biotech, Inc.
Cancer of Head and Neck
Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention
This is an open-label randomized phase II multicenter trial. An estimated 350 patients deemed to be in complete remission at month 3 after curative treatment are considered for this trial.
- Trial name
- DietINT (NCT02869399)
- Testing
- dietary intervention in addition to standard recommendations
- Where
- 6 sites in Austria, Germany and 4 more
- Volunteers
- 94 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Head and Neck Small Cell Carcinoma, Sarcopenia
Impact of Low Muscle Mass in HNC Treated With Immunotherapy
The purpose of the study is to evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with…
- Trial name
- IMMUNONUTRI (NCT04721184)
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Institut Català d'Oncologia
Advanced/Metastatic Solid Tumors, Bladder Cancer
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT07090499
- Testing
- PF-08046876, Pembrolizumab, Cisplatin
- Where
- 31 sites in United States, Canada and 4 more
- Volunteers
- 540 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
- Trial name
- NCT02105636
- Testing
- Nivolumab, Cetuximab, Methotrexate
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 361 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Squamous Cell of Head and Neck
PD 0332991 and Cetuximab in Patients With Incurable SCCHN
The purpose of this Phase I/II study is to define the maximum tolerated dose of PD 0332991 given with cetuximab and evaluated the side effects of the combination.
- Trial name
- NCT02101034
- Testing
- Cetuximab, PD 0332991
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Head and Neck Neoplasms
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)
Study Objectives: To determine the MTD (maximal tolerated dose) and recommended dose of a weekly docetaxel and cisplatin combination regimen for locoregional recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck…
- Trial name
- NCT00268671
- Testing
- Docetaxel
- Volunteers
- 45 people
- Sponsor
- Sanofi
Squamous Cell Carcinoma of the Head and Neck
Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT04672772
- Testing
- Cetuximab, Paclitaxel
- Where
- 20 sites in Spain
- Volunteers
- 531 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Advanced Solid Tumor
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.
- Trial name
- NCT04349267
- Testing
- BMS-986315, nivolumab, cetuximab
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Neoplasms, Cancer of the Head and Neck
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer
The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best…
- Trial name
- NCT01283334
- Testing
- Carboplatin, Cetuximab, RAD001
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
Carcinoma, Squamous Cell, Oral Cancer
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
Participants in this study have a type of cancer called squamous cell carcinoma of the head and neck (SCCHN). Their SCCHN has spread around the area where the cancer first started. This is called locally-advanced SCCHN.
- Conditions
- Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer
- Trial name
- NCT03174275
- Testing
- Durvalumab, Carboplatin, Nab-paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
This was an open-label, phase Ib, multicenter clinical trial to determine the MTD/RDE of the orally administered c-MET inhibitor INC280 in combination with cetuximab.
- Trial name
- NCT02205398
- Testing
- INC280, cetuximab
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
S0217, Adjuvant Cisplatin and Docetaxel After Complete Resection Stage III or IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- S0217 (NCT00084435)
- Testing
- cisplatin, docetaxel, radiation therapy
- Where
- 29 sites in United States
- Sponsor
- SWOG Cancer Research Network
Head and Neck Cancer
Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is to support current and future Zalutumumab studies by increasing the Pharmacokinetic (PK) knowledge of the drug. PK is the study of how a drug is absorbed (taken up), distributed (moved around), metabolised (broken…
- Trial name
- NCT01054625
- Testing
- zalutumumab
- Where
- 7 sites in Belgium, Hungary and 2 more
- Volunteers
- 31 people
- Sponsor
- Genmab
Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery
This phase I trial evaluates the side effects of NT-I7 in treating patients with squamous cell carcinoma of head and neck that has come back (recurrent) who are undergoing surgery.
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT04588038
- Testing
- Efineptakin alfa
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Hyunseok Kang, MD
Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck
Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab…
- Trial name
- NCT02289209
- Testing
- Reirradiation, MK-3475
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dan Zandberg
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Cancer, Head and Neck Cancer
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to estimate, with pre-specified precision, the difference in local-regional control (LRC) rate at 2 years in subjects receiving chemoradiotherapy (CRT) or panitumumab plus radiotherapy (PRT) as first…
- Conditions
- Cancer, Head and Neck Cancer, Oncology, Squamous Cell Carcinoma
- Trial name
- NCT00547157
- Testing
- Panitumumab, Cisplatin
- Volunteers
- 152 people
- Sponsor
- Amgen